PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals is a U.S.-based clinical-stage biotechnology company focused on developing small-molecule cancer therapies, with an emphasis on genomically defined tumors. The company was incorporated in Delaware and is headquartered in Princeton, New Jersey, where it advances its research, development, and future commercialization plans.

10.09

10.09

— PMV Pharmaceuticals, Inc.
%
Clinical-stage oncology product candidates100% Investigational small-molecule cancer therapies being developed for genomically defined tumors.
Preclinical research and discovery0% Early-stage discovery work to identify and validate additional oncology candidates.
Future commercialization activities0% Planned sales, marketing, and distribution activities for any approved products.

PMV Pharmaceuticals is not yet a commercial seller; its eventual customers would be oncologists, cancer centers, and...

  • Oncologists and oncology practicesprimary

    They would prescribe targeted therapies like rezatapopt for patients whose tumors match the drug's biomarker profile.

  • Cancer hospitals and treatment centersprimary

    They would administer approved oncology drugs and integrate them into treatment pathways for defined patient populations.

  • Companion diagnostic partnerssecondary

    They would collaborate on tests used to identify eligible patients for genomically targeted treatment.

  • Third-party commercial collaboratorssecondary

    They may help market, distribute, or commercialize approved products if PMV does not build a full internal sales force.

PMV Pharmaceuticals is headquartered in Princeton, New Jersey and operates as a U.S.-based development company...

  • •Headquartered in Princeton, New Jersey, United States
  • •Core development activities are managed from the U.S.
  • •Third-party manufacturing sourcing includes China exposure
  • •Future commercialization may extend to U.S. and overseas markets
  • •No revenue geography disclosed because the company has no product sales

The company’s strategy is to advance its oncology pipeline through preclinical and clinical development, with...

01
Advance rezatapopt through development and approvalshort-term

The company’s value creation depends on proving clinical benefit and obtaining regulatory approval for its lead candidate.

02
Secure intellectual property protectionmedium-term

Patent and exclusivity protection are central to preserving commercial rights in a competitive targeted-therapy market.

03
Establish commercialization capabilitymedium-term

If approved, the company needs sales, marketing, and distribution capabilities to reach oncologists and treatment centers.

PMV Pharmaceuticals faces the typical risks of a clinical-stage biotech company: development failure, regulatory delay,...

critical

Clinical development failure

The company has no approved products and depends on successful clinical outcomes for rezatapopt and future candidates.

Scope
Lead oncology pipeline
Materiality
high
high

Regulatory approval delay or denial

Drug candidates must clear lengthy FDA and other regulatory processes before commercialization.

Scope
Rezatapopt and future product candidates
Materiality
high
high

Competitive pressure in targeted oncology

Rivals may develop more effective, safer, or faster-approved therapies for genomically defined cancers.

Scope
Oncology pipeline
Materiality
high
high

China manufacturing and sourcing exposure

A portion of chemistry-based development and raw-material sourcing occurs in China through third parties.

Scope
Third-party manufacturers and raw materials
Materiality
high
high

Financing and dilution risk

The company has no product revenue and relies on external capital to fund development.

Scope
Cash runway and future financings
Materiality
high
Research and development expense recognition
Affects operating loss and comparability across periods
Capitalized R&D advance payments
Can shift expense recognition between periods
Stock-based compensation
Affects R&D, G&A, and dilution analysis
Fair value of marketable securities
Impacts liquidity presentation and net interest income

Enliven Therapeutics, Inc.

ELVN · Pharmaceutical Preparations

Perspective Therapeutics, Inc.

CATX · Pharmaceutical Preparations

Nuvation Bio Inc.

NUVB · Pharmaceutical Preparations

Tempest Therapeutics, Inc.

TPST · Pharmaceutical Preparations

Nuvalent, Inc.

NUVL · Pharmaceutical Preparations

Nuvectis Pharma, Inc.

NVCT · Pharmaceutical Preparations

: 29/04/2026